Taiji Group's controlled subsidiary Southwest Pharmaceutical has obtained the drug registration certificate for Butorphanol Tartrate Injection issued by the National Medical Products Administration. The drug is a chemical drug Class 3 injection, with specifications including 1ml:1mg and 2ml:4mg, indicated for the treatment of cancer pain and postoperative pain, and is listed as a Category B drug under national medical insurance. Southwest Pharmaceutical becomes the sixth company in China to be approved for production of this drug, following five other companies that have already launched the product. The company has invested a cumulative R&D expenditure of 9.2421 million yuan on this product. In the first quarter of 2026, Taiji Group achieved revenue of 2.528 billion yuan and a net profit attributable to the parent company of 65.62 million yuan.
Chongqing Taiji Industry Group Co LtdSubsidiary obtains registration certificate for new drug, expanding product portfolio.
